BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 17294127)

  • 1. Long-term pharmacological activation of PPARgamma does not prevent left ventricular remodeling in dogs with advanced heart failure.
    Suzuki G; Khanal S; Rastogi S; Morita H; Mishima T; Anagnostopoulos PV; Nass O; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2007 Feb; 21(1):29-36. PubMed ID: 17294127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2000 Jan; 35(1):222-9. PubMed ID: 10636284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of chronic neutral endopeptidase inhibition on the progression of left ventricular dysfunction and remodeling in dogs with moderate heart failure.
    Mishima T; Tanimura M; Suzuki G; Todor A; Sharov VG; Tanhehco EJ; Goldstein S; Sabbah HN
    Cardiovasc Drugs Ther; 2002 May; 16(3):209-14. PubMed ID: 12374898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.
    Rastogi S; Imai M; Sharov VG; Mishra S; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2008 Dec; 295(6):H2475-82. PubMed ID: 18952719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction.
    Sabbah HN; Shimoyama H; Kono T; Gupta RC; Sharov VG; Scicli G; Levine TB; Goldstein S
    Circulation; 1994 Jun; 89(6):2852-9. PubMed ID: 8205701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing-induced model of canine heart failure.
    Shirasaka T; Miyagawa S; Fukushima S; Saito A; Shiozaki M; Kawaguchi N; Matsuura N; Nakatani S; Sakai Y; Daimon T; Okita Y; Sawa Y
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):413-21. PubMed ID: 23541854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart failure.
    Morita H; Khanal S; Rastogi S; Suzuki G; Imai M; Todor A; Sharov VG; Goldstein S; O'Neill TP; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2006 Jun; 290(6):H2522-7. PubMed ID: 16428338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment.
    Sabbah HN; Sharov VG; Gupta RC; Mishra S; Rastogi S; Undrovinas AI; Chaudhry PA; Todor A; Mishima T; Tanhehco EJ; Suzuki G
    Circ Res; 2003 Nov; 93(11):1095-101. PubMed ID: 14563716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ranolazine combined with enalapril or metoprolol prevents progressive LV dysfunction and remodeling in dogs with moderate heart failure.
    Rastogi S; Sharov VG; Mishra S; Gupta RC; Blackburn B; Belardinelli L; Stanley WC; Sabbah HN
    Am J Physiol Heart Circ Physiol; 2008 Nov; 295(5):H2149-55. PubMed ID: 18820026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure.
    Suzuki G; Mishima T; Tanhehco EJ; Sharov VG; Todor A; Rostogi S; Gupta RC; Chaudhry PA; Anagnostopoulos PV; Nass O; Goldstein S; Sabbah HN
    Br J Pharmacol; 2003 Jan; 138(2):301-9. PubMed ID: 12540520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of AT1-receptor blockade on progression of left ventricular dysfunction in dogs with heart failure.
    Tanimura M; Sharov VG; Shimoyama H; Mishima T; Levine TB; Goldstein S; Sabbah HN
    Am J Physiol; 1999 Apr; 276(4):H1385-92. PubMed ID: 10199866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atenolol is inferior to metoprolol in improving left ventricular function and preventing ventricular remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Mishra S; Wang M; Sharov VG; Gupta RC; Goldstein S; Sabbah HN
    Cardiology; 2009; 112(4):294-302. PubMed ID: 18832825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure.
    Zacà V; Rastogi S; Imai M; Wang M; Sharov VG; Jiang A; Goldstein S; Sabbah HN
    J Am Coll Cardiol; 2007 Aug; 50(6):551-7. PubMed ID: 17678740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Rastogi S; Zhang K; Zimmermann K; Diedrichs N; Albrecht-Küpper BE
    Circ Heart Fail; 2013 May; 6(3):563-71. PubMed ID: 23564604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
    Shiomi T; Tsutsui H; Hayashidani S; Suematsu N; Ikeuchi M; Wen J; Ishibashi M; Kubota T; Egashira K; Takeshita A
    Circulation; 2002 Dec; 106(24):3126-32. PubMed ID: 12473562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of Peroxisome Proliferator-activated Receptor γ Prevents Development of Heart Failure With Preserved Ejection Fraction; Inhibition of Wnt-β-catenin Signaling as a Possible Mechanism.
    Kamimura D; Uchino K; Ishigami T; Hall ME; Umemura S
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):155-61. PubMed ID: 27046338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beta-blocker improves survival, left ventricular function, and myocardial remodeling in hypertensive rats with diastolic heart failure.
    Kobayashi M; Machida N; Mitsuishi M; Yamane Y
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1112-9. PubMed ID: 15607617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure.
    McMahon WS; Holzgrefe HH; Walker JD; Mukherjee R; Arthur SR; Cavallo MJ; Child MJ; Spinale FG
    J Am Coll Cardiol; 1996 Aug; 28(2):495-505. PubMed ID: 8800131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure.
    Sabbah HN; Gupta RC; Kohli S; Wang M; Hachem S; Zhang K
    Circ Heart Fail; 2016 Feb; 9(2):e002206. PubMed ID: 26839394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.